SynopsisIclusig is an oral drug developed by ARIAD Pharmaceuticalsfor the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia(ALL). The global Iclusig market was valued at US$ 241 million in 2023 an.....
SynopsisMarqibo (vinCRIStine sulfate LIPOSOME injection) is vincristine encapsulated in sphingomyelin/cholesterol liposomes for intravenous administration. The global Vincristine Sulfate Liposome Injection market was valued at US$ 332 million in 2023 and is anti.....
SynopsisMarqibo (vinCRIStine sulfate LIPOSOME injection) is vincristine encapsulated in sphingomyelin/cholesterol liposomes for intravenous administration. The global Vincristine Sulfate Liposome Injection Drugs market was valued at US$ 332 million in 2023 and i.....
SynopsisMarqibo (vinCRIStine sulfate LIPOSOME injection) is vincristine encapsulated in sphingomyelin/cholesterol liposomes for intravenous administration. The global Marqibo market was valued at US$ 211 million in 2023 and is anticipated to reach US$ 351.2 mill.....
SynopsisPegaspargase is a modified enzyme used as an antineoplastic agent. It is a form of L-asparaginase which has undergone PEGylation. The global Pegaspargase market was valued at US$ 284 million in 2023 and is anticipated to reach US$ 505.9 million by 2030, .....
SynopsisPegaspargase is a modified enzyme used as an antineoplastic agent. It is a form of L-asparaginase which has undergone PEGylation. The global Pegaspargase Drugs market was valued at US$ 284 million in 2023 and is anticipated to reach US$ 505.9 million by .....
SynopsisMercaptopurine, a nucleoside metabolic inhibitor, known chemically as 1,7-dihydro-6H-purine-6-thione monohydrate, is an analogue of the purine bases adenine and hypoxanthine. The global Mercaptopurine Oral Solution market was valued at US$ 418 million in.....
SynopsisMercaptopurine, a nucleoside metabolic inhibitor, known chemically as 1,7-dihydro-6H-purine-6-thione monohydrate, is an analogue of the purine bases adenine and hypoxanthine. The global Mercaptopurine Oral Solution Drugs market was valued at US$ 418 mill.....
SynopsisMercaptopurine, a nucleoside metabolic inhibitor, known chemically as 1,7-dihydro-6H-purine-6-thione monohydrate, is an analogue of the purine bases adenine and hypoxanthine. The global Purixan market was valued at US$ 412 million in 2023 and is anticipa.....
SynopsisMercaptopurine, a nucleoside metabolic inhibitor, known chemically as 1,7-dihydro-6H-purine-6-thione monohydrate, is an analogue of the purine bases adenine and hypoxanthine. The global Mercaptopurine market was valued at US$ 418 million in 2023 and is a.....
